Cantor Fitzgerald Comments on BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a note issued to investors on Monday, July 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($3.48) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Cantor Fitzgerald also issued estimates for Beam Therapeutics' FY2026 earnings at ($2.92) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.13). Beam Therapeutics had a negative net margin of 609.24% and a negative return on equity of 44.24%. The firm had revenue of $7.47 million during the quarter, compared to analyst estimates of $14.69 million. During the same period in the prior year, the company posted ($1.21) earnings per share. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year.

A number of other brokerages also recently issued reports on BEAM. Wells Fargo & Company cut their target price on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research note on Monday, April 7th. Barclays cut their target price on Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Bank of America raised Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 target price for the company in a research note on Friday, March 28th. Finally, Guggenheim cut their target price on Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $48.75.

Beam Therapeutics Price Performance

NASDAQ BEAM traded up $0.77 during mid-day trading on Wednesday, hitting $21.72. The stock had a trading volume of 1,623,416 shares, compared to its average volume of 2,500,295. Beam Therapeutics has a twelve month low of $13.52 and a twelve month high of $35.25. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -4.71 and a beta of 2.07. The firm's 50 day moving average is $18.41 and its 200 day moving average is $21.40.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Beam Therapeutics in the fourth quarter valued at about $43,000. Sterling Capital Management LLC lifted its position in shares of Beam Therapeutics by 816.0% during the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock worth $60,000 after purchasing an additional 2,146 shares in the last quarter. CWM LLC lifted its position in shares of Beam Therapeutics by 79.8% during the first quarter. CWM LLC now owns 2,684 shares of the company's stock worth $52,000 after purchasing an additional 1,191 shares in the last quarter. Amalgamated Bank lifted its position in shares of Beam Therapeutics by 20.4% during the first quarter. Amalgamated Bank now owns 3,153 shares of the company's stock worth $62,000 after purchasing an additional 534 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Beam Therapeutics by 43.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,884 shares of the company's stock worth $66,000 after purchasing an additional 1,175 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company's stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.